Veracyte (NASDAQ:VCYT) Downgraded by Zacks Research to “Hold”

Posted by George Bondi on Jul 15th, 2026

Zacks Research cut shares of Veracyte (NASDAQ:VCYT – Free Report) from a strong-buy rating to a hold rating in a report issued on Monday morning,Zacks.com reports.

Other equities research analysts also recently issued research reports about the stock. Guggenheim lifted their target price on shares of Veracyte from $45.00 to $65.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Jefferies Financial Group started coverage on Veracyte in a report on Monday, April 13th. They set a “buy” rating and a $45.00 price target on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Veracyte in a research note on Wednesday, June 24th. Morgan Stanley lifted their price objective on Veracyte from $37.00 to $47.00 and gave the stock an “underweight” rating in a report on Thursday, July 9th. Finally, Wolfe Research assumed coverage on Veracyte in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $55.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $54.43.

Read Our Latest Analysis on Veracyte

Veracyte Stock Performance

VCYT opened at $56.62 on Monday. The company’s 50-day simple moving average is $49.63 and its two-hundred day simple moving average is $41.05. The stock has a market capitalization of $4.52 billion, a P/E ratio of 51.94 and a beta of 1.93. Veracyte has a 52-week low of $22.61 and a 52-week high of $60.91.

Veracyte (NASDAQ:VCYT – Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.18. Veracyte had a net margin of 16.25% and a return on equity of 9.07%. The firm had revenue of $139.07 million during the quarter, compared to analyst estimates of $130.36 million. During the same period in the previous year, the business posted $0.31 earnings per share. The business’s revenue for the quarter was up 21.5% on a year-over-year basis. Research analysts forecast that Veracyte will post 1.28 EPS for the current fiscal year.

Insider Buying and Selling at Veracyte

In other news, Director Karin Eastham sold 3,729 shares of Veracyte stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $52.89, for a total transaction of $197,226.81. Following the transaction, the director owned 15,097 shares in the company, valued at $798,480.33. This trade represents a 19.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Rebecca Chambers sold 3,561 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $49.73, for a total value of $177,088.53. Following the completion of the sale, the chief financial officer owned 173,280 shares of the company’s stock, valued at $8,617,214.40. This trade represents a 2.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 206,696 shares of company stock valued at $10,079,058 in the last quarter. Insiders own 1.60% of the company’s stock.

Institutional Trading of Veracyte

Hedge funds have recently bought and sold shares of the stock. Fuller & Thaler Asset Management Inc. bought a new stake in Veracyte during the 4th quarter worth approximately $58,158,000. First Trust Advisors LP boosted its position in shares of Veracyte by 64.9% in the first quarter. First Trust Advisors LP now owns 2,117,046 shares of the biotechnology company’s stock worth $68,190,000 after purchasing an additional 833,543 shares during the period. Squarepoint Ops LLC increased its stake in shares of Veracyte by 770.6% in the second quarter. Squarepoint Ops LLC now owns 897,387 shares of the biotechnology company’s stock worth $24,256,000 after purchasing an additional 794,307 shares in the last quarter. Soleus Capital Management L.P. purchased a new stake in shares of Veracyte in the second quarter worth $19,338,000. Finally, Iron Triangle Partners LP raised its position in shares of Veracyte by 102.1% during the 4th quarter. Iron Triangle Partners LP now owns 980,391 shares of the biotechnology company’s stock valued at $41,274,000 after purchasing an additional 495,391 shares during the period.

Veracyte Company Profile

(Get Free Report)

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.